Narrow diameter implants may be at increased risk of overload due to occlusal forces; therefore, implants with higher fatigue strength may be beneficial. The aim of this observational study was to evaluate survival and success of narrow diameter (Ø 3.3 mm) TiZr alloy (Roxolid, Institut Straumann AG, Basel, Switzerland) implants for 2 years in daily dental practice. This was a prospective, non-interventional, multicenter study; no specific patient inclusion or exclusion criteria were applied. Each patient received at least one TiZr implant; the treatment plan, including implant loading and final restoration, was at the investigator's discretion. The primary outcome was implant survival and success after 1 year. Secondary outcomes included 2-year survival and success and marginal bone level change. A total of 603 implants were placed in 357 patients. Cumulative survival and success rates were 97.8% and 97.6%, respectively, after 1 year and 97.6% and 97.4%, respectively, after 2 years. Bone levels remained stable in the majority of patients, and soft tissue remained stable up to 2 years. Within the limitations of a non-interventional study design, TiZr implants showed excellent survival and success with minimal bone loss up to 2 years in daily dental practice. The results compare favorably with those of small-diameter implants in controlled clinical trials.
Keywords: Roxolid; SLActive surface; narrow diameter implants; non-interventional; titanium-zirconium (TiZr).